Icon Stock Earnings Reports

ICON reported Q4 and full-year 2025 results, disclosed the findings and remediation plan from an internal investigation into revenue recognition and controls, and provided 2026 guidance. The investigation (covering Q3 2023–Q4 2024 and into 2025) identified improper adjustments and errors related to clinical services revenue timing, cost-to-complete estimates, realizable value inputs and presentation of certain contract assets/liabilities; the net overstatement totaled $65M in 2023 and $93M in 2024. Management identified material weaknesses in internal controls and has implemented a remediation plan (organizational changes, revised revenue policies, training, and tighter controls over manual adjustments). Financially, Q4 revenue was $2.1B (+2.5% YoY), with adjusted EBITDA and margins pressured by a mix shift (notably higher pass-through revenue) and the cost-to-complete estimate updates (impacting Q4 by over $50M). Net bookings were strong at $2.9B (+19% YoY) with a book-to-bill of ~1.36x and improved win rates (notably a 5-point sequential uplift in biotech). Cancellations declined meaningfully in Q4. ICON guided 2026 revenue of $7.85B–$8.15B and adjusted EPS of $10–$11, flagged near-term headwinds from prior award pricing and mix (FSO/FSP and pass-throughs), and expects EBITDA margin around ~16.5% at the midpoint for 2026 with sequential margin improvement through the year. The company completed the divestiture of Symphony Health, will retain access to relevant data through a partner, continues to invest in labs, early phase capacity and AI-enabled capabilities, and prioritizes disciplined capital allocation including share repurchases.